{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:07:12Z","timestamp":1778670432094,"version":"3.51.4"},"reference-count":13,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,4,23]],"date-time":"2008-04-23T00:00:00Z","timestamp":1208908800000},"content-version":"vor","delay-in-days":4161,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Genetics"],"published-print":{"date-parts":[[1996,12]]},"abstract":"<jats:p>A unique substitution of glycine 934 by glutamic acid in the triple helical domain of type III collagen was identified in a proband with Ehlers\u2010Danlos syndrome type IV. The substitution was due to the transition of G 3302 to A in \u03b1 1 (III) cDNA which is encoded by exon 46 of COL3A1. It resulted in a severe deficiency of type III collagen in fibroblast cultures and dermis. Dilatation of the endoplasmic reticulum of the dermal fibroblasts was probably due to the failure of these cells to secrete type III collagen molecules containing one or more mutant \u03b1 1(III) chains. The dermal collagen fibrils were narrow, but their constituent type III collagen molecules contained predominantly normal \u03b1 1(III) chains. As a result, the major effect of the substitution of glycine 934 by glutamic acid was to severely reduce the amount of normal type III collagen available for the formation of heterotypic collagen fibrils in the extracellular matrix.<\/jats:p>","DOI":"10.1111\/j.1399-0004.1996.tb02709.x","type":"journal-article","created":{"date-parts":[[2010,7,19]],"date-time":"2010-07-19T06:26:32Z","timestamp":1279520792000},"page":"442-445","source":"Crossref","is-referenced-by-count":7,"title":["Abnormal extracellular matrix in Ehlers\u2010Danlos syndrome type IV due to the substitution of glycine 934 by glutamic acid in the triple helical domain of type III collagen"],"prefix":"10.1111","volume":"50","author":[{"given":"J.","family":"McGrory","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Weksberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Thorner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. G.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,4,23]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2600509"},{"key":"e_1_2_1_3_1","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1016\/S0021-9258(18)48196-3","article-title":"Lethal osteogenesis imperfecta due to a substitution of arginine for glycine at residue 391 of the *a1(I) chain of type I collagen","volume":"262","author":"Bateman JF","year":"1987","journal-title":"J Biol Chem"},{"key":"e_1_2_1_4_1","first-page":"336","article-title":"Altered secretion of type III procollagen in a form of type IV Ehlers\u2010Danlos syndrome","volume":"44","author":"Byers PH","year":"1981","journal-title":"Lab Invest"},{"key":"e_1_2_1_5_1","doi-asserted-by":"crossref","first-page":"17070","DOI":"10.1016\/S0021-9258(17)44870-8","article-title":"A base substitution at a splice site in the COL3A1 gene causes exon skipping and generates abnormal type III procollagen in a patient with Ehlers\u2010Danlos type IV","volume":"265","author":"Cole WG","year":"1990","journal-title":"J Biol Chem"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1990.tb17927.x"},{"key":"e_1_2_1_7_1","first-page":"342","article-title":"Ultrastructural characteristics of the skin in a form of Ehlers\u2010Danlos syndrome type IV","volume":"44","author":"Holbrook KA","year":"1981","journal-title":"Lab Invest"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02435995"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114863"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12320704"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/3.3.511"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320460308"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0344-0338(11)80749-1"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00194313"}],"container-title":["Clinical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-0004.1996.tb02709.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-0004.1996.tb02709.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T10:29:39Z","timestamp":1698402579000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-0004.1996.tb02709.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,12]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1996,12]]}},"alternative-id":["10.1111\/j.1399-0004.1996.tb02709.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-0004.1996.tb02709.x","archive":["Portico"],"relation":{},"ISSN":["0009-9163","1399-0004"],"issn-type":[{"value":"0009-9163","type":"print"},{"value":"1399-0004","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,12]]}}}